The decision of the US Federal Health Service to proceed their recommendation for suspension of Johnson & Johnson vaccine use, caused a stir in Europe. In this context, the Commission is asking for clarifications from the company for its “completely unexpected” announcement that it will delay the delivery of its preparations, as a European official told Reuters.
Couple of minutes ago, The US company said in a statement that it would delay the release of its vaccine in Europe and examines, in cooperation with the European Health Service, cases of very rare thromboembolism in vaccinated persons.
The European official said the company had confirmed last Friday that it intended to deliver 55 million doses of its vaccine to the EU, as stipulated in its contract, by the end of June.
“The European Commission is in contact with the company” to get clarifications on its decision, he added, asking not to be named because these discussions are confidential.
According to the Athenian-Macedonian News Agency, a Commission spokesman said the commission was looking into the matter but could not comment further at this time.
“The benefits of the vaccine outweigh the potential risks”
THE Dutch Drug Regulatory Authority (CBG) announced today that its benefits Johnson & Johnson vaccine against COVID-19 outweigh the potential risks, following the recommendation of the US authorities.
“Together with the European Medicines Agency (EMA) we are monitoring the situation very closely,” CBG said, according to Reuters and the Athens News Agency. “At present, the benefits of the vaccine outweigh the potential risks.”
In Spain Prime Minister Pedro Sanchez said today that the benefits of all approved COVID-19 vaccines offset the risks, following the recommendation of US authorities to suspend vaccination with the drug developed by Johnson & Johnson.
Sanchez added, however, that authorities would slow down the availability of vaccines to assess the risks if and when serious side effects are reported.
THE Sweden will decide how to use the vaccine against her COVID-19 of Johnson & Johnson in the coming days, the Health Service announced today, following reports of rare blood clots similar to those reported for the AstraZeneca vaccine.
The decision comes a week after European regulators announced they had found a possible link between AstraZeneca’s COVID-19 vaccine and a rare blood clotting problem that led to a small number of deaths.
Sweden is expected to receive the first doses of the Johnson & Johnson vaccine later this week. Stop using it AstraZeneca vaccine in March, but later resumed its administration to people aged 65 and over.
“We are looking at the issue and the available data from the European Medicines Agency and our American colleagues,” Sweden’s chief epidemiologist Anders Tegnel told a news conference. “A decision is expected in a day or a few.”
Normally vaccinations are currently available in Belgium
The first 36,000 doses of Johnson & Johnson were delivered to Belgium yesterday (Monday) and vaccinations are expected to begin next week, rtl reports.
Despite new information from the United States, no change in planning is currently foreseen.
“We are closely monitoring the situation,” said Gudron Bright, a spokesman for the vaccination task force. “At the moment, we have not received any indication that we should stop vaccination.”
Waiting stop in Berlin
The German Ministry of Health has not yet decided how to handle the issue of the Johnson & Johnson vaccine, after the US decision to suspend its administration, said the spokesman Hanno Kauts.
Answering a question in the context of informing the authors, Mr. Kauts referred to the Paul Ehrlich Institute, which, as he said, is responsible for the issue. Asked about the decision taken by the Bavarian government to continue the vaccine, Mr. Kautz said that the Institute’s recommendations have federal force.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
